HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
Share
Why It Matters
An analyst who covers Sagimet thinks the stock is a good buy. They still believe it could reach $29 per share sometime ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.